|
Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A U.S. tertiary oncology center analysis. |
|
|
Consulting or Advisory Role - Astellas Medivation; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen; Novartis; Pfizer; Tempus |
Research Funding - Bayer (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - GE Healthcare (I); Johnson & Johnson (I) |
Research Funding - Bayer (Inst) |
|
|
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen Scientific Affairs (Inst); Mallinckrodt (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst) |
|
|
Research Funding - Bayer (Inst) |
|
|
Research Funding - Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst) |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
|
Stock and Other Ownership Interests - Bayer; Pfizer |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Pfizer; Progenics; Research to Practice; UpToDate |
Consulting or Advisory Role - AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate |
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals |